研究目的
Investigating the clinical value of simultaneous PET imaging in high-risk prostate cancer staging using 11C-choline PET/MRI.
研究成果
The metabolic information provided by 11C-choline PET imaging in integrated PET/MR scans shows significant correlations with the PSA level. Metabolic volumetric parameters such as MTV and UVP can serve as imaging biomarkers and show a prognostic value and may show better correlations in combination with MR imaging parameters.
研究不足
1. Most high-risk PCa patients did not undergo prostatectomy, and the number of patients with surgical specimens was small.
2. The treatment was not standardized in all patients.
3. The follow-up durations were relatively short (mean follow-up duration, 25.5 months).
1：Experimental Design and Method Selection:
The study was a retrospective analysis of a prospective study involving 31 high-risk prostate cancer patients who underwent 11C-choline PET/MRI for staging purposes. The methodology included the analysis of clinical characteristics and imaging parameters from PET and MRI.
2：Sample Selection and Data Sources:
Patients with pathologically proven high-risk prostate cancer according to the D’Amico Risk Classification were included. Data were acquired from PET/MRI scans.
3：List of Experimental Equipment and Materials:
An integrated PET/MRI system (Biograph mMR; Siemens Healthcare, Erlangen, Germany) was used for scanning. Patients received a single intravenous bolus of 10–20 mCi (370–740 MBq) 11C-choline.
4：Experimental Procedures and Operational Workflow:
PET scans were performed from the mid-thigh to the head in five bed positions with simultaneous MRI. Postprocessing for DWI and DCE-MRI was performed using the software integral to the MRI unit.
5：Data Analysis Methods:
The PMOD 3.3 software package was used for tumor segmentation. Statistical analysis was performed using the Spearman’s correlation method and Cox regression analysis.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
